SynthesisBMC gastroenterology2020
Proportion of NAFLD patients with normal ALT value in overall NAFLD patients: a systematic review and meta-analysis.
Synthesis in BMC gastroenterology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 93 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
93 citing papers in PubMed, 1 synthesis or guideline pooled it, 154 citations in OpenAlex.
- The benefit of metformin in the treatment of pediatric non-alcoholic fatty liver disease: a systematic review and meta-analysis of randomized controlled trials.European journal of pediatrics · 2023Pooled it
- Cardiometabolic health, visceral fat and circulating irisin levels: results from a real-world weight loss study.Journal of endocrinological investigation · 2021Trial
- Identifying MASLD Patients with MASH or Significant Fibrosis: The Role of Lower ALT Thresholds.Journal of clinical medicine · 2026Article
- Cardiovascular disease and metabolic dysfunction-associated steatotic liver disease incidence in metabolically healthy and unhealthy normal weight obesity.International journal of obesity (2005) · 2026Article
- Determinants of Metabolic Dysfunction-Associated Steatotic Liver Diseases in Patients with Type 2 Diabetes Mellitus.Journal of clinical medicine · 2026Article
- Cardiometabolic comorbidity and health outcomes of persons with metabolic dysfunction-associated steatotic liver disease (MASLD) in Ontario, Canada.Canadian liver journal · 2026Article
- Comparison of the diagnostic performance of alanine aminotransferase and ultrasonography for discrimination of liver biopsy proven metabolic associated steatotic liver disease: a ROC curve analysis.BMC endocrine disorders · 2026Article
- Alanine Aminotransferase Elevation at Diagnosis of Youth-Onset Type 2 Diabetes: Prevalence, Predictors, and One-Year Outcomes.Endocrinology, diabetes & metabolism · 2026Article
- Development and external validation of a predictive model for in-hospital mortality in patients with liver cirrhosis and sepsis.Scientific reports · 2026Article
- Fighting the epidemic of pediatric metabolic dysfunction-associated steatotic liver disease: Role of non-invasive diagnostics and early pharmacological intervention.World journal of hepatology · 2026Review
- Prevalence and factors associated with metabolic dysfunction-associated fatty liver disease in a multiethnic Asian country.Scientific reports · 2026Article
- Evolving burden of metabolic dysfunction-associated steatotic liver disease and its complications in a US nationwide healthcare system.Hepatology communications · 2026Article
- Evaluation for Fatty Liver Infiltration Should Become Standard in Pediatric Cholecystectomy Patients.Cureus · 2025Article
- Metabolic dysfunction-associated steatotic liver disease in individuals with type 2 diabetes mellitus and diabetic foot ulcers: prevalence and associated factors.Journal of diabetes and metabolic disorders · 2025Article
- Albumin Reduces Hepatic Steatosis and Inflammation in High-Fat-Diet-Fed Mice.International journal of molecular sciences · 2025Article
- Consensus Statement on Metabolic Dysfunction-Associated Steatotic Liver Disease in Children and Adolescents From the Joint TASL-TSPGHAN Expert Committee.JGH open : an open access journal of gastroenterology and hepatology · 2025Article
- Therapeutic effects of curcumin supplementation on liver enzymes of nonalcoholic fatty liver disease patients: A systematic review and meta-analysis of randomized clinical trials.Food science & nutrition · 2025Review
- Association between GNRI and risk of non-alcoholic fatty liver disease in non-obese individuals: a Chinese longitudinal prospective cohort study.Frontiers in nutrition · 2025Article
- Evaluation of autoimmune phenomena in patients with nonalcoholic fatty liver disease on the basis of liver pathology.World journal of hepatology · 2024Article
- [Serum indices of hepatic steatosis in indigenous Venezuelan adults of the Piaroa ethnic group]Revista de la Facultad de Ciencias Medicas (Cordoba, Argentina) · 2024Article
33 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
backgroundALT value is often used to reflect the hepatic inflammation and injury in NAFLD patients, but many studies proved that ALT values were normal in many NAFLD patients. The aim of this study was to identify the summarized proportion of NAFLD patients with normal ALT value in the overall NAFLD patients.
methodsElectronic databases PubMed, EMBASE, Ovid, and the Cochrane Library were searched for potential studies published from January 1, 2000 to September 30, 2019. Studies that have reported the number of NAFLD or NASH patients with normal and abnormal ALT value were included and analyzed. Abstracts, reviews, case reports, and letters were excluded.
resultsA total of 11 studies with 4084 patients were included for assessing the summarized proportion of NAFLD patients with normal ALT in overall NAFLD patients. As the results shown, the summarized proportion of NAFLD patients with normal ALT value in overall NAFLD patients was 25% (95%CI: 20-31%) which was calculated by the random-effects model. The summarized proportion of NASH patients with normal ALT value in overall NASH patients was 19% (95%CI: 13-27%). Subgroup analysis includes region, study type, diagnostic method, and group size were conducted to investigate the resource of heterogeneity in the summarized proportion of NAFLD and NASH patients with normal ALT value.
conclusions25% NAFLD patients and 19% NASH patients possess the normal ALT value in the clinical manifestation. The value of ALT in the clinical diagnosis of NAFLD and NASH remains need be further testified.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.